Step-and-shoot Intensity-modulated Radiation Therapy Research Articles

Evaluation of internal margins for prostate for step and shoot intensity-modulated radiation therapy and volumetric modulated arc therapy using different margin formulas.

PurposeThis feasibility study evaluated the intra‐fractional prostate motion using an ultrasound image‐guided system during step and shoot intensity‐modulated radiation therapy (SS‐IMRT) and volumetric modulated arc therapy (VMAT). Moreover, the internal margins (IMs) using different margin formulas were calculated.MethodsFourteen consecutive patients with prostate cancer who underwent SS‐IMRT (n = 5) or VMAT (n = 9) between March 2019 and April 2020 were considered. The intra‐fractional prostate motion was observed in the superior–inferior (SI), anterior–posterior (AP), and left–right (LR) directions. The displacement of the prostate was defined as the displacement from the initial position at the scanning start time, which was evaluated using the mean ± standard deviation (SD). IMs were calculated using the van Herk and restricted maximum likelihood (REML) formulas for SS‐IMRT and VMAT.ResultsFor SS‐IMRT, the maximum displacements of the prostate motion were 0.17 ± 0.18, 0.56 ± 0.86, and 0.18 ± 0.59 mm in the SI, AP, and LR directions, respectively. For VMAT, the maximum displacements of the prostate motion were 0.19 ± 0.64, 0.22 ± 0.35, and 0.14 ± 0.37 mm in the SI, AP, and LR directions, respectively. The IMs obtained for SS‐IMRT and VMAT were within 2.3 mm and 1.2 mm using the van Herk formula and within 1.2 mm and 0.8 mm using the REML formula.ConclusionsThis feasibility study confirmed that intra‐fractional prostate motion was observed with SS‐IMRT and VMAT using different margin formulas. The IMs should be determined according to each irradiation technique using the REML margin.

Evaluation of MU2net as an online secondary dose check for MR guided radiation therapy with the Elekta unity MR linac.

During the adaptive workflow associated with MRgRT, a secondary dose calculation is required and MU2net (DOSIsoft, France) is one commercial option. The suitability of MU2net to be used in conjunction with the online Monaco treatment planning system of the Elekta Unity (Elekta AB, Stockholm, Sweden), is evaluated in this work. Monaco and MU2net point doses are compared for various fields on and off axis and at different SSDs. To investigate the comparative effects of attenuation due to the cryostat, couch and posterior coil, measured, MU2net and Monaco dose outputs at the isocentre, as a function of gantry angle, were compared. Point doses for the beams of nine step and shoot IMRT (SSIMRT) test plans (courtesy Elekta) were calculated with Monaco v5.4 and compared to corresponding doses computed with MU2net. In addition, Monaco v5.4 and MU2net point doses were compared for 1552 beams treated on the Unity at our facility. For the on-axis fields investigated the agreement between MU2net and measured data is acceptable. MU2net and Monaco point doses for the Elekta SSIMRT test plans were within ± 5.0% and ± 6.4% for beams delivered from gantry zero and at planned beam angles, respectively. For the 1552 beams delivered approximately 80.0% of MU2net and Monaco point doses agree within ± 5.0%, therefore it is recommended to correlate MU2net Dose Reference Points (DRPs) with pre and post treatment dosimetry verification. Computational accuracy of MU2net could be enhanced with improved modelling of attenuation due to the couch, cryostat and posterior MR imaging coil.

Correlation between plan quality improvements and reduced acute dysphagia and xerostomia in the definitive treatment of oropharyngeal squamous cell carcinoma.

To evaluate plan quality using volumetric-modulated arc therapy (VMAT) and step-and-shoot intensity-modulated radiation therapy (SS-IMRT) techniques and for patients treated for oropharyngeal squamous cell carcinoma (OPSCC). Treatment plans for patients treated definitively for stages I-IVb, OPSCC between December 2009 and August 2015 were retrospectively reviewed. Dosimetric endpoints of involved organs-at-risk (OARs) were retrieved from clinical plans. Common Terminology Criteria for Adverse Events scores of acute toxicities were compared. Two-hundred twenty-two patients were identified with 134 and 88 receiving SS-IMRT and VMAT with median follow-up time of 23.0 and 7.9 months, respectively. The dosimetric endpoints of the OARs were significantly improved in VMAT cohort, which translated into significantly lower rates of grade 2 or higher acute dysphagia and xerostomia. Improvements in stages I-IVb, oropharyngeal cancer plan quality are associated with reduced grade ≥ 2 acute dysphagia and xerostomia.

Radiation treatment planning and delivery strategies for a pregnant brain tumor patient.

The management of a pregnant patient in radiation oncology is an infrequent event requiring careful consideration by both the physician and physicist. The aim of this manuscript was to highlight treatment planning techniques and detail measurements of fetal dose for a pregnant patient recently requiring treatment for a brain cancer. A 27‐year‐old woman was treated during gestational weeks 19–25 for a resected grade 3 astrocytoma to 50.4 Gy in 28 fractions, followed by an additional 9 Gy boost in five fractions. Four potential plans were developed for the patient: a 6 MV 3D‐conformal treatment plan with enhanced dynamic wedges, a 6 MV step‐and‐shoot (SnS) intensity‐modulated radiation therapy (IMRT) plan, an unflattened 6 MV SnS IMRT plan, and an Accuray TomoTherapy HDA helical IMRT treatment plan. All treatment plans used strategies to reduce peripheral dose. Fetal dose was estimated for each treatment plan using available literature references, and measurements were made using thermoluminescent dosimeters (TLDs) and an ionization chamber with an anthropomorphic phantom. TLD measurements from a full‐course radiation delivery ranged from 1.0 to 1.6 cGy for the 3D‐conformal treatment plan, from 1.0 to 1.5 cGy for the 6 MV SnS IMRT plan, from 0.6 to 1.0 cGy for the unflattened 6 MV SnS IMRT plan, and from 1.9 to 2.6 cGy for the TomoTherapy treatment plan. The unflattened 6 MV SnS IMRT treatment plan was selected for treatment for this particular patient, though the fetal doses from all treatment plans were deemed acceptable. The cumulative dose to the patient's unshielded fetus is estimated to be 1.0 cGy at most. The planning technique and distance between the treatment target and fetus both contributed to this relatively low fetal dose. Relevant treatment planning strategies and treatment delivery considerations are discussed to aid radiation oncologists and medical physicists in the management of pregnant patients.

A 7-Year Institutional Experience in Dosimetric Quality Improvement for Oropharyngeal Cancer: Progress to Date

We have previously reported a low incidence of treatment-related toxic effects after treatment for oropharyngeal carcinoma compared to historical data. Multiple quality improvement steps have been taken at our institution over the past 7 years: the adoption of volumetric modulated arc therapy (VMAT) over step-and-shoot IMRT (SS-IMRT), daily image guidance, improved planning algorithms and the implementation of a specialized dosimetry team. Here we present temporal trends in improvement and factors associated with benefit. 222 patients treated definitively for oropharyngeal carcinoma from December 2009 through August 2016 were identified from an IRB-approved registry. Each patient was planned with a two or three-dose level prescription delivered to planned target volumes (PTVs) of gross tumor, microscopic high-risk, or low-risk nodes. Specialized planners were designated for treatment planning after July 2013, while VMAT was gradually adopted after June 2014. Treatment plan quality was reviewed based on tumor coverage and dosimetric endpoints to organs-at-risk (OARs). The evolutions of the endpoints over 7 years were also evaluated. Wilcoxon signed-rank test was used to compare the differences in non-parametric continuous variables and Spearman’s rho test for correlations. 134 patients were treated with SS-IMRT and 88 with VMAT. The PTVs were well covered by the prescription doses (average conformity index: 1.02±0.02). Significant dose reductions in multiple OARs were observed in the patients treated with VMAT (see Table). No statistically-significant differences in the dosimetric endpoints were found between the patients planned by specialized planners (average p>0.05). Furthermore, negative correlations between all the endpoints and treatment date were identified, indicating a temporal trend towards better OAR sparing. The results were consistent with our previous clinical observation of the reduced occurrences of treatment related toxicity. Our results demonstrate that the adoption of VMAT significantly improved OAR sparing for oropharyngeal cancer patients, which is a contributing factor for the declining incidences of treatment related toxicity. Other factors such as planning algorithms and the adoption of specialized planners likely contributed but to a lesser degree.Abstract 2787; TableMedian (Gy)VMATMedian (Gy)SS-IMRTWilcoxon test p-valueSpearman correlation coefficientSpearman test p-valueBrainstem D0.03cc20.026.4<0.0001-0.38<0.0001Spinal cord D0.03cc33.341.5<0.0001-0.68<0.0001Larynx Dmean26.636.0<0.0001-0.61<0.0001Supraglottis Dmean39.246.4<0.0001-0.27<0.0001Oral cavity Dmean32.836.60.04-0.170.02OARpharynx Dmean45.752.6<0.0001-0.46<0.0001Contralateral submandibular Dmean37.238.20.72-0.070.57Contralateral parotid Dmean24.225.40.09-0.46<0.0001 Open table in a new tab

Clinical implications of the overshoot effect for treatment plan delivery and patient-specific quality assurance for step-and-shoot IMRT.

In this work, overshoot and undershoot effects associated with step‐and‐shoot IMRT (SSIMRT) delivery on a Varian Clinac 21iX are investigated, and their impact on patient‐specific QA point dose measurements and treatment plan delivery are evaluated. Pinnacle3 SSIMRT plans consisting of 5, 10, and 15 identical 5×5 cm2 MLC defined segments and MU/segment values of 5 MU, 10 MU, and 20 MU were utilized and delivered at 600/300 MU/min. Independent of the number of segments the overshoot and undershoot at 600 MU/min were approximately ±10%,±5%, and ±2.5% for 5 MU/segment, 10 MU/segment, and 20 MU/segment, respectively. At 300 MU/min, each of these values is approximately halved. Interfractional variation of these effects (10 fractions), as well as dosimetric variations for intermediate segments, are reduced at the lower dose rate. QA point‐dose measurements for a sample (n=29) of head and neck SSIMRT beams were on average 2.9% (600 MU/min) and 1.7% (300 MU/min) higher than Pinnacle3 planned doses. In comparison for prostate beams (n=46), measured point doses were 0.8% (600 MU/min) and 0.4% (300 MU/min) higher. The reduction in planned‐measured point‐dose discrepancies at 300 MU/min can be attributed in part to the inclusion of the first segment (overshoot) in the admixture of segments that deliver measured dose. Pinnacle3 plans for 10/9 head and neck/prostate treatments were adjusted by ±0.5 MU to include the effects of overshoot and undershoot at 600 MU/min. Comparing original and adjusted plans for each site indicated that the original plan was preferred in 70% and 89% of head and neck and prostate cases, respectively. The disparity between planned and delivered treatment that this suggests can potentially be mitigated by treating SSIMRT at a dose rate below 600 MU/min.PACS number(s): 87.55.Qr, 87.56.bd, 87.56.N‐

SU-F-T-356: DosimetricComparison of VMAT Vs Step and Shoot IMRT Plans for Stage III Lung CancerPatients with Mediastinal Involvement

Purpose: For Stage III lung cancers that entail treatment of some or all of the mediastinum, anterior-posterior focused Step and Shoot IMRT (SS-IMRT) and VMAT plans have been clinically used to deliver the prescribed dose while working to minimize lung dose and avoid other critical structures. A comparison between the two planning methods was completed to see which treatment method is superior and minimizes dose to healthy lung tissue. Methods: Ten patients who were recently treated with SS-IMRT or VMAT plans for Stage III lung cancer with mediastinal involvement were selected. All patients received a simulation CT for treatment planning, as well as a 4D CT and PET/CT fusion for target delineation. Plans were prescribed 6250 cGy in 25 fractions and normalized such that 100% of the prescription dose covered 95% of the PTV. Clinically approved SS-IMRT or VMAT plans were then copied and planned using the alternative modality with identical optimization criteria. SS-IMRT plans utilized seven to nine beams distributed around the patient while the VMAT plans consisted of two full 360 degree arcs. Plans were compared for the lung volume receiving 20 Gy (V20). Results: Both SS-IMRT and VMAT can be used to achieve clinical treatment plans for patients with Stage III Lung cancer with targets encompassing the mediastinum. VMAT plans produced an average V20 of 23.0+/−8.3% and SS-IMRT produced an average of 24.2+/−10.0%. Conclusion: Results indicate that either method can achieve comparable dose distributions, however, VMAT can allow the optimizer to distribute dose over paths of minimal lung tissue and reduce the V20. Therefore, creating a VMAT with constraints identical to an SS-IMRT plan could help to reduce the V20 in clinical treatment plans.

In vivo measurement of dose distribution in patients' lymphocytes: helical tomotherapy versus step-and-shoot IMRT in prostate cancer.

In radiotherapy, in vivo measurement of dose distribution within patients' lymphocytes can be performed by detecting gamma-H2AX foci in lymphocyte nuclei. This method can help in determining the whole-body dose. Options for risk estimations for toxicities in normal tissue and for the incidence of secondary malignancy are still under debate. In this investigation, helical tomotherapy (TOMO) is compared with step-and-shoot IMRT (SSIMRT) of the prostate gland by measuring the dose distribution within patients' lymphocytes. In this prospective study, blood was taken from 20 patients before and 10 min after their first irradiation fraction for each technique. The isolated leukocytes were fixed 2 h after radiation. DNA double-stranded breaks in lymphocyte nuclei were stained immunocytochemically using anti-gamma-H2AX antibodies. Gamma-H2AX foci distribution in lymphocytes was determined for each patient. Using a calibration line, dose distributions in patients' lymphocytes were determined by studying the gamma-H2AX foci distribution, and these data were used to generate a cumulative dose–lymphocyte histogram (DLH). Measured in vivo (DLH), significantly fewer lymphocytes indicated low-dose exposure (<40% of the applied dose) during TOMO compared with SSIMRT. The dose exposure range, between 45 and 100%, was equal with both radiation techniques. The mean number of gamma-H2AX foci per lymphocyte was significantly lower in the TOMO group compared with the SSIMRT group. In radiotherapy of the prostate gland, TOMO generates a smaller fraction of patients' lymphocytes with low-dose exposure relative to the whole body compared with SSIMRT. Differences in the constructional buildup of the different linear accelerator systems, e.g. the flattening filter, may be the cause thereof. The influence of these methods on the incidence of secondary malignancy should be investigated in further studies.

SU-E-T-128: Dosimetric Evaluation of MLC Modeling in Pinnacle V9.2 for Varian TrueBeam STx

Purpose: To evaluate the effects of MLC modeling after commissioning the Varian TrueBeam LINAC in Pinnacle version 9.2. Methods: Stepand-shoot IMRT QAs were investigated when we observed our measured absolute dose results using ion chamber (Capintec PR-05P) were uncharacteristically low; about 4–5% compared to doses calculated by Pinnacle3 (Phillips, Madison, WI). This problem was predominant for large and highly modulated head & neck (HN) treatments. Intuitively we knew this had to be related to shortcomings in the MLC modeling in Pinnacle. Using film QA we were able to iteratively adjust the MLC parameters. We confirmed results by re-testing five failed IMRT QA patients; and ion chamber measurements were verified in Quasar anthropomorphic phantom. Results: After commissioning the LINAC in Pinnacle version 9.2, the MLC transmission for 6X, 10X and 15X were 2.0%, 1.7% and 2.0%, respectively, and additional Interleaf leakage for all three energies was 0.5%. These parameters were obtained from profiles scanned with an Edge detector (Sun Nuclear, Melbourne, FL) during machine commissioning. A Verification testing with radiographic EDR2 film (Kodak, Rochester, NY) measurement was performed by creating a closed MLC leaf pattern and analyzing using RIT software (RIT, Colorado Springs, CO). This reduced MLC transmission for 6X, 10X and 15X to 0.7%, 0.9% and 0.9%, respectively; while increasing additional Interleaf leakage for all three energies to 1.0%. Conclusion: Radiographic film measurements were used to correct MLC transmission values for step & shoot IMRT fields used in Pinnacle version 9.2. After adjusting the MLC parameters to correlate with the film QA, there was still very good agreement between the Pinnacle model and commissioning data. Using the same QA methodology, we were also able to improve the beam models for the Varian C-series linacs, Novalis_Tx, and TrueBeam M-120 linacs.

Conditions for reliable time‐resolved dosimetry of electronic portal imaging devices for fixed‐gantry IMRT and VMAT

The continuous scanning mode of electronic portal imaging devices (EPID) that offers time-resolved information has been newly explored for verifying dynamic radiation deliveries. This study seeks to determine operating conditions (dose rate stability and time resolution) under which that mode can be used accurately for the time-resolved dosimetry of intensity-modulated radiation therapy (IMRT) beams. The authors have designed the following test beams with variable beam holdoffs and dose rate regulations: a 10 × 10 cm open beam to serve as a reference beam; a sliding window (SW) beam utilizing the motion of a pair of multileaf collimator (MLC) leaves outside the 10 × 10 cm jaw; a step and shoot (SS) beam to move the pair in step; a volumetric modulated arc therapy (VMAT) beam. The beams were designed in such a way that they all produce the same open beam output of 10 × 10 cm. Time-resolved ion chamber measurements at isocenter and time-resolved and integrating EPID measurements were performed for all beams. The time-resolved EPID measurements were evaluated through comparison with the ion chamber and integrating EPID measurements, as the latter are accepted procedures. For two-dimensional, time-resolved evaluation, a VMAT beam with an infield MLC travel was designed. Time-resolved EPID measurements and Monte Carlo calculations of such EPID dose images for this beam were performed and intercompared. For IMRT beams (SW and SS), the authors found disagreement greater than 2%, caused by frame missing of the time-resolved mode. However, frame missing disappeared, yielding agreement better than 2%, when the dose rate of irradiation (and thus the frame acquisition rates) reached a stable and planned rate as the dose of irradiation was raised past certain thresholds (a minimum 12 s of irradiation per shoot used for SS IMRT). For VMAT, the authors found that dose rate does not affect the frame acquisition rate, thereby causing no frame missing. However, serious inplanar nonuniformities were found. This could be overcome by sacrificing temporal resolution (10 frames or 0.95 s/image): the continuous images agreed with ion chamber responses at the center of EPID and the calculation two-dimensionally in a time-resolved manner. The authors have determined conditions under which the continuous mode can be used for time-resolved dosimetry of fixed-gantry IMRT and VMAT and demonstrated it for VMAT.

SU‐E‐T‐616: Dosimetric Comparison of Volumetric Modulated Arc Therapy, Step‐And‐Shoot, and Sliding Window IMRT for Prostate Cancer

Purpose: To evaluate treatment plans generated by Step‐and‐Shoot (SS), Sliding Window (SW) and Volumetric Modulated Arc Therapy (VMAT) in order to assess the differences in dose volume histograms of planning target volume (PTV) and organs at risk (OAR), conformity indices, radiobiological evaluations, normal tissue dose, and plan quality for prostate cancer cases. Methods: Ten prostate cancer patients treated in our center were selected for this retrospective study. Treatment plans were generated with Eclipse version 8.9 using 10 MV photon beams. For VMAT, Varian Rapid Arc with 1 or 2 arcs, and for SS and SW IMRT, 7ndash;9 coplanar fields were used. Each plan had three PTVs with prescription doses of 81, 59.4, and 45 Gy to prostate, to prostate and lymph nodes, and to pelvis, respectively. Doses to PTV, OAR, normal tissues, and the conformal indices (COIN) were compared among three techniques. The equivalent uniform dose (EUD), tumor control probability (TCP), and normal tissue complication probability (NTCP) were calculated and compared. Results: The average mean doses to the PTV prostate were 82.8 Gy and the average differences of mean dose among all techniques were below 0.3 Gy. For bladder and rectum, the percent differences of average mean dose among all techniques were below 2.2%, though high dose rectal volumes were reduced for VMAT. The COIN slightly favoured VMAT. The average TCP varied by less than 0.001%. The average NTCP for the rectum was 3.55%, 3.75% and 3.87% for VMAT, SS and SW, respectively, while the differences in the average NTCP for the bladder was negligible. The full body volumes receiving 20 to 30 Gy were reduced in VMAT treatments. Conclusion: Data indicates similar target coverage and OAR sparing in general. Additional patients will continue to be added to the study. Variation in normal tissue distribution was less than expected.

Poster - Thur Eve - 53: Analysis of the distribution of dose delivery during respiratory-gated step-and-shoot IMRT for lung cancer radiotherapy.

Respiratory motion is a large source of dosimetric error when treating lung cancer with Intensity Modulated Radiation Therapy (IMRT). The asynchronicity of the tumour motion and the multileaf collimator (MLC) used to modulate the radiation beam intensity, leads to the interplay effect. One method to account for this effect is respiratory gating. Treatment planning optimization for gated IMRT is performed on a subset average 4D-CT which includes the phases surrounding end exhalation. However, this assumes that the beam delivery will be evenly distributed amongst those phases. This study investigates the distribution of beam delivery during gated step-and-shoot IMRT (SS-IMRT) for both early and late stage non-small cell lung cancer (NSCLC). Four Stage I NSCLC patients, prescribed a dose of 54 Gy in 3 fractions, and five Stage III NSCLC patients, prescribed a dose of 60 Gy in 30 fractions, were retrospectively planned with high and low modulation beams-IMRT, and delivered using the QUASAR™ Programmable Respiratory Motion Platform with 15 mm and 20 mm peak-to-peak sinusoidal motion and real patient breathing motion. The percent monitor units delivered at each phase were compared. For Stage I patients, the monitor units delivered were evenly distributed over the gating window due to a high number of monitor units delivered per control point. For Stage III patients, as the complexity of SS-IMRT increases, there were more monitor units delivered in the initial gating phase. This dose discrepancy could potentially lead to geographic miss of the tumour and should be taken into account during treatment planning.

SU-E-T-577: Dosimetric Comparison of Volumetric Modulated Arc Therapy (VMAT), Step and Shoot and Sliding Window IMRT for Prostate Cancer.

This study aims to evaluate treatment plans generated by Step- and-Shoot (SS), Sliding Window (SW) and Volumetric Modulated Arc Therapy (VMAT) in order to assess the differences in dose volume histograms of planning target volume (PTV) and organs at risk (OAR), conformity indices, radiobiological evaluations, and plan quality for prostate cancer cases. Six prostate cancer patients treated in our center were selected for this retrospective study. Treatment plans were generated with Eclipse version 8.9 using 10 MV photon beams. For VMAT, Varian Rapid Arc with 1 or 2 arcs, and for SS and SW IMRT, 7-9 fields were used. Each plan had three PTVs with prescription doses of 81, 59.4, and 45 Gy to prostate, to prostate and lymph nodes, and to pelvis, respectively. Doses to PTV and OAR and the conformal indices (COIN) were compared among three techniques. The equivalent uniform dose (EUD), tumor control probability (TCP) and normal tissue complication probability (NTCP) was also calculated and compared. The mean doses to the PTV prostate on average were 83 Gy and the percent differences of mean dose among all techniques were below 0.28. For bladder and rectum, the percent differences of mean dose among all techniques were below 2.2. The COIN did not favour any particular delivery method over the other. The TCP was higher with SS and SW for four patients and higher with VMAT for two patients. The NTCP for the rectum was the lowest with VMAT in all patients except one. Preliminary data shows similar target coverage in general. We will extend our study to include 15 patients to compare different approaches with statistics. We will attempt to define characteristics predictive of the superior delivery technique.

A study of segment weight optimization with the CMS XiO step‐and‐shoot IMRT technique for prostate cancer

The aim of this study was to compare IMRT optimization in the CMS XiO radiotherapy treatment planning system, with and without segment weight optimization. Twenty‐one prostate cancer patients were selected for this study. All patients were initially planned with step‐and‐shoot IMRT (S‐IMRT). A new plan was then created for each patient by applying the segment weight optimization tool (SWO‐IMRT). Analysis was performed on the (SWO‐IMRT) and (S‐IMRT) plans by comparing the total number of segments, monitor units, rectal and bladder dose. The study showed a statistically significant reduction in the total number of segments (mean: 25.3%; range: 16.8%–31.1%) with SWO‐IMRT as compared to S‐IMRT (p<0.0001). Similarly, a mean reduction of 3.8% (range: 0.4%–7.7%) in the total MU was observed with SWO‐IMRT (p<0.0001). The study showed an average rectal dose decrease of 13.7% (range: 7.9%–21.4%) with SWO‐IMRT (p<0.0001). We also observed a statistically significant reduction of 26.7% (range: 16.0%–41.4%; p < 0.0001) in the mean dose to the posterior one‐third rectum and an overall reduction in mean bladder dose of 2.2% (range: 0.1%–6.1%) for SWO‐IMRT (p<0.0001). This study shows that the segment weight optimization method significantly reduces the total number of segments and the dose to the rectum for IMRT prostate cancer. It also resulted in fewer monitor units for most of the prostate cases observed in this study.PACS numbers: 85.55.ne; 87.55.de; 87.55.kd

Dosimetric Study Of Helical Tomotherapy, Step And Shoot Intensity Modulated Radiation Therapy And Three-dimensional Conformal Radiation Therapy For Liver Cancers

Image-guided helical tomotherapy (HT) technology has been widely used in the clinical treatments. Treatment benefits have been observed in the management of head and neck, lung and pelvic cancers. HT, compared with step and shoot intensity-modulated radiation therapy (SaS-IMRT) and three-dimensional conformal radiation therapy (3D-CRT), had certain dosimetric advantages of its unique gantry-ring design. This study aims to investigate the dosimetric characteristics of HT, SaS-IMRT and 3D-CRT during the treatment of liver tumor as well as their dose distribution comparison of the associated critical normal tissues.

Clinical Dosimetric Study of Three Radiotherapy Techniques for Postoperative Breast Cancer: Helical Tomotherapy, IMRT, and 3D-CRT

This paper is to investigate the dosimetric characteristics of Helical Tomotherapy (HT), step-and-shoot intensity-modulated radiation therapy (SaS-IMRT) and three-dimensional conformal radiation therapy (3D-CRT) for the postoperative breast cancer as well as their dosimetric comparison of the normal tissues. CT images of 10 postoperative patients with early stage breast cancer were transferred into HT, SaS-IMRT and 3D-CRT planning systems respectively after the target region and normal tissues were outlined by the same physician to assure the contour consistency. Each prescribed dose for three different modalities of plans was given to a total of 50 Gy in 25 fractions. Doses and irradiated volumes in heart, lungs, as well as conformity index (CI) and homogeneity index (HI) were evaluated for detailed comparison. All three plans showed appropriate coverage for the prescribed target dose in the dosimetric comparison. The CI in HT and SaS-IMRT as well as 3D-CRT was 0.68 ± 0.12, 0.58 ± 0.08 and 0.40 ± 0.08, respectively. The HI were 1.10 ± 0.03, 1.14 ± 0.02 and 1.17 ± 0.04, which appeared intergroup significant differences (p < 0.05). V₅, V₁₀, as well as V₂₀ of the heart were smallest in 3D-CRT than HT and SaS-IMRT. V5 of the ipsilateral lung was the smallest in 3D-CRT than HT and SaS-IMRT (p < 0.05); However, V₂₀ and V₃₀ were smaller in HT and SaS-IMRT than 3D-CRT (p < 0.05). V₅ of the contralateral lung was the smallest in 3D-CRT than other groups, with V₁₀~V₃₀ were basically similar in numeric values with not obvious discrepancy. Comparing with SaS-IMRT and 3D-CRT, HT technique in treating breast cancer had the best conformity and homogeneity index as well as steepest dose gradient due to its highly modulated beamlets with rotational technique. The heart volume irradiated was the smallest in conventional 3D-CRT, with SaS-IMRT was the largest among the three techniques, as expected. The volume of the contralateral lung irradiated was the smallest in 3D-CRT than other groups. V₅ of the ipsilateral lung was the smallest in 3D-CRT than other two groups. V₁₀~V₃₀ in HT and SaS-IMRT were similar and better than 3D-CRT dosimetrically. We conclude that HT technique had advantages over SaS-IMRT and 3D-CRT based on the dosimetric comparison in this study, especially in the high dose region of ipsilateral lung, target homogeneity and dose uniformity.

Helical tomotherapy for head and neck squamous cell carcinoma: Dosimetric comparison with linear accelerator-based step-and-shoot IMRT

Linear Accelerator-based Intensity Modulated Radiation Therapy (IMRT), either as step-and shoot (SS) or in dynamic mode, is now considered routine in the definitive management of head and neck squamous cell carcinoma (HNSCC). Helical TomoTherapy (HT) is a new platform to deliver IMRT. This study aims to compare step-and-shoot Intensity Modulated Radiation Therapy (SS IMRT) with dynamic Helical TomoTherapy (HT) dosimetrically in patients with head and neck squamous cell carcinoma (HNSCC). Twelve patients with HNSCC, previously treated with SS IMRT, were re-planned on HT using the same CT dataset. Plans were compared for target coverage and organs-at-risk (OARs) sparing. Sparing of parotids was assessed after stratifying for side (contralateral vs. ipsilateral) and site of disease (laryngopharynx vs. oropharynx). Normal tissue complication probabilities (NTCP) were also compared for the parotid glands. All HT plans showed improvement in target coverage and homogeneity, and reduction in OAR doses as compared to SS IMRT plans. For PTV 66, the mean V 99 improved by 14.65% ( P = 0.02). Dose Homogeneity (D 10-90 ) was significantly better in the HT plans (mean 2.07Gy as compared to 4.5Gy in the SS IMRT plans, P = 0.02). HT resulted in an average reduction of mean parotid dose of 12.66Gy and 18.28Gy for the contralateral and ipsilateral glands ( P = 0.003) respectively. This translated into a 24.09% and 35.22% reduction in Normal Tissue Complication Probability (NTCP) for the contralateral and ipsilateral parotids respectively ( P < 0.01). Site of disease (laryngopharynx vs. oropharynx) did not have any significant impact on parotid sparing between SS IMRT and HT. The maximum dose to the spinal cord showed a mean reduction of 12.07Gy in HT plans ( P = 0.02). Helical Tomotherapy achieved better target coverage with improved OAR sparing as compared to SS IMRT. The significant reduction in mean parotid doses translated into meaningful reduction in NTCP, with potential clinical implications in terms of reduction in Xerostomia and improved quality of life in patients with HNSCC.

Dosimetric comparison between helical tomotherapy and step-and-shoot intensity modulated radiation therapy for endometrial carcinoma

Helical tomotherapy (HT) has shown its dosimetric advantages in the radiotherapy for many cancers. To date, no published studies have performed a dosimetric evaluation of whole pelvic radiotherapy (WPRT) using HT for postoperative endometrial cancer. This study was to compare the dosimetric characteristics of HT and step-and-shoot intensity modulated radiation therapy (SaS-IMRT) for endometrial cancer patients undergoing postoperative WPRT, and to explore whether whole pelvic HT for postoperative endometrial cancer has the advantage of dosimetry. Ten patients with endometrial cancer undergoing postoperative WPRT were enrolled in this study. SaS-IMRT and HT Plans were developed for each patient. The dose distributions of the targets, organs at risk and normal tissue were analyzed and compared. The mean PTV100 were 95.6% and 95.8% (P=0.72) for the SaS-IMRT and HT plans, respectively. The mean homogeneity indexes were 1.10 and 1. 07 (P=0.00). The mean conformity indexes were both 0.87. The mean doses to rectum and bladder for HT were decreased by 1.3 Gy and 3.0 Gy compared with SaS-IMRT, respectively, while the mean dose to pelvic bones was increased by 1.1 Gy. The volumes of small intestine and colon, pelvic bones receiving moderate and low dose also increased. The V5, V10 and V20 of normal tissue were increased by 13.0%, 18.0%, and 5.0% (P=0.00). The mean dose to normal tissue was increased by 2.5 Gy (P=0.00). Compared with SaS-IMRT, HT resulted in more homogeneous PTV dose distribution, better sparing of rectum and bladder. The volumes of small intestine and colon, pelvic bones and normal tissue receiving moderate and low dose for HT increased. The clinical significance of the dosimetric differences needs further investigations.

Integration of Real-Time Internal Electromagnetic Position Monitoring Coupled With Dynamic Multileaf Collimator Tracking: An Intensity-Modulated Radiation Therapy Feasibility Study

Continuous tumor position measurement coupled with a tumor tracking system would result in a highly accurate radiation therapy system. Previous internal position monitoring systems have been limited by fluoroscopic radiation dose and low delivery efficiency. We aimed to incorporate a continuous, electromagnetic, three-dimensional position tracking system (Calypso 4D Localization System) with a dynamic multileaf collimator (DMLC)-based dose delivery system. A research version of the Calypso System provided real-time position of three Beacon transponders. These real-time three-dimensional positions were sent to research MLC controller with a motion-tracking algorithm that changed the planned leaf sequence. Electromagnetic transponders were embedded in a solid water film phantom that moved with patient lung trajectories while being irradiated with two different plans: a step-and-shoot intensity-modulated radiation therapy (S-IMRT) field and a dynamic IMRT (D-IMRT) field. Dosimetric results were recorded under three conditions: no intervention, DMLC tracking, and a spatial gating system. Dosimetric accuracy was comparable for gating and DMLC tracking. Failure rates for gating/DMLC tracking are as follows: +/-3 cGy 10.9/ 7.5% for S-IMRT, 3.3/7.2% for D-IMRT; gamma (3mm/3%) 0.2/1.2% for S-IMRT, 0.2/0.2% for D-IMRT. DMLC tracking proved to be as efficient as standard delivery, with a two- to fivefold efficiency increase over gating. Real-time target position information was successfully integrated into a DMLC effector system to modify dose delivery. Experimental results show both comparable dosimetric accuracy as well as improved efficiency compared with spatial gating.

Use of MV and kV imager correlation for maintaining continuous real-time 3D internal marker tracking during beam interruptions

The integration of onboard kV imaging together with a MV electronic portal imaging device (EPID) on linear accelerators (LINAC) can provide an easy to implement real-time 3D organ position monitoring solution for treatment delivery. Currently, real-time MV–kV tracking has only been demonstrated by simultaneous imagining by both MV and kV imaging devices. However, modalities such as step-and-shoot IMRT (SS-IMRT), which inherently contain MV beam interruptions, can lead to loss of target information necessary for 3D localization. Additionally, continuous kV imaging throughout the treatment delivery can lead to high levels of imaging dose to the patient. This work demonstrates for the first time how full 3D target tracking can be maintained even in the presence of such beam interruption, or MV/kV beam interleave, by use of a relatively simple correlation model together with MV–kV tracking. A moving correlation model was constructed using both present and prior positions of the marker in the available MV or kV image to compute the position of the marker on the interrupted imager. A commercially available radiotherapy system, equipped with both MV and kV imaging devices, was used to deliver typical SS-IMRT lung treatment plans to a 4D phantom containing internally embedded metallic markers. To simulate actual lung tumor motion, previous recorded 4D lung patient motion data were used. Lung tumor motion data of five separate patients were inputted into the 4D phantom, and typical SS-IMRT lung plans were delivered to simulate actual clinical deliveries. Application of the correlation model to SS-IMRT lung treatment deliveries was found to be an effective solution for maintaining continuous 3D tracking during ‘step’ beam interruptions. For deliveries involving five or more gantry angles with 50 or more fields per plan, the positional errors were found to have ⩽1 mm root mean squared error (RMSE) in all three spatial directions. In addition to increasing the robustness of MV–kV tracking against beam interruption, it was also found that use of correlation can be an effective way of lowering kV dose to the patient and for increasing kV image quality by reduction of MV scatter interference.